Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

DelveInsight's CD47 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...

While the best companies are hard to find, but they can generate massive returns over long periods. To wit, the BioNTech SE ...

BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who ...

Below we explain how we will communicate with you. We set out how we use your data in our Privacy Policy. Global City Media, and its associated brands will use the ...

mRNA specialist BioNTech has driven its partnership with UK artificial intelligence InstaDeep into top gear, agreeing to buy the company outright in a cash and equity deal that values it at up to ...

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling ...

The CDK7 inhibitors market is anticipated to experience substantial growth in the coming years. This growth is driven by a rise in cancer diagnoses, promising results from early-phase clinical ...

But the court ruled another similar patent was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022.

Specific financials of the deal were not disclosed. BioNTech's cancer push continues, coughing up $200M for OncoC4's CTLA-4 antibody The merger adds AI-081, a preclinical bispecific antibody ...